ID: ALA5272410

Max Phase: Preclinical

Molecular Formula: C10H8ClN3

Molecular Weight: 205.65

Associated Items:

Representations

Canonical SMILES:  Nc1ccc(-c2ccc(Cl)nc2)cn1

Standard InChI:  InChI=1S/C10H8ClN3/c11-9-3-1-7(5-13-9)8-2-4-10(12)14-6-8/h1-6H,(H2,12,14)

Standard InChI Key:  TYYJYMGEQUZGJK-UHFFFAOYSA-N

Associated Targets(Human)

PI3-kinase p110-delta subunit 6699 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 205.65Molecular Weight (Monoisotopic): 205.0407AlogP: 2.38#Rotatable Bonds: 1
Polar Surface Area: 51.80Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 6.25CX LogP: 1.77CX LogD: 1.75
Aromatic Rings: 2Heavy Atoms: 14QED Weighted: 0.73Np Likeness Score: -0.42

References

1. Yang C, Gong Y, Gao Y, Deng M, Liu X, Yang Y, Ling Y, Jia Y, Zhou Y..  (2023)  Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ inhibitors for hematological cancer.,  82  [PMID:36706844] [10.1016/j.bmcl.2023.129152]

Source